Table 3. Follow-up data, according to treatment modality at baselinea

3 mo12 mo24 mo36 mo
a Measurements and follow-up times during treatment, according to the modality at 3 mo, were considered [as-treated (AT) censoring]. Values are means and 95% confidence intervals (CI).
No. at risk
    HD742572372232
    PD480357205111
Davies score (intermediate/high) (%)
    HD50.1/11.649.7/10.548.9/9.750.0/11.6
    PD34.2/7.134.7/7.632.7/8.834.2/4.5
Presence of cardiovascular morbidity (%)
    HD40.842.345.448.7
    PD25.426.328.325.2
Hemoglobin level (g/dl)
    HD10.7 (10.6 to 10.8)11.4 (11.2 to 11.5)11.3 (11.2 to 11.4)11.3 (11.1 to 11.4)
    PD11.9 (11.8 to 12.1)11.9 (11.7 to 12.0)11.7 (11.5 to 11.9)11.7 (11.4 to 12.0)
Albumin level (g/dl)
    HD3.66 (3.62 to 3.69)3.72 (3.68 to 3.76)3.64 (3.59 to 3.68)3.65 (3.59 to 3.71)
    PD3.64 (3.59 to 3.69)3.66 (3.60 to 3.71)3.62 (3.55 to 3.69)3.57 (3.49 to 3.66)
SGA (scale of to 7)
    HD5.7 (5.6 to 5.8)6.0 (5.9 to 6.1)6.1 (6.0 to 6.2)6.1 (6.0 to 6.2)
    PD6.2 (6.1 to 6.3)6.4 (6.3 to 6.4)6.3 (6.2 to 6.4)6.3 (6.1 to 6.5)
Renal Kt/V (weekly)
    HD0.70 (0.65 to 0.74)0.48 (0.44 to 0.53)0.34 (0.29 to 0.40)0.32 (0.22 to 0.43)
    PD0.82 (0.77 to 0.87)0.64 (0.57 to 0.70)0.55 (0.47 to 0.63)0.53 (0.41 to 0.65)